Jeff Ludwig Gets a Grant from Compensation Committee of Puma’s Board of Directors
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical firm, introduced that in reference to the appointment of Jeff Ludwig as Puma’s Chief Industrial Officer, the Compensation Committee of Puma’s Board of Directors authorized a reward to Mr. Ludwig of an inducement inventory choice to buy 320,000 shares of Puma widespread inventory, at a train worth per share equal to the closing value of Puma’s widespread inventory on the grant date. The choice was granted on March 20, 2020, underneath Puma’s 2017 Employment Inducement Incentive Award Plan, adopted on April 27, 2017, and supplies for the granting of fairness awards to new staff of Puma.
The choice is scheduled to vest over a 3-year period, with one-third of the shares underlying the choice vesting on March 16, 2021, and 1/36 of the shares underlying the choice vesting on every month-to-month anniversary thereafter, topic to continued employment (and additional topic to accelerated vesting on a qualifying termination of employment in reference to a change in charge of Puma). The choice was granted as an inducement that was a fabric element of Mr. Ludwig’s determination to join in Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. is a biopharmaceutical firm with a deal with the event and commercialization of progressive products to reinforce cancer care. The Company in-licenses the worldwide growth and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357. Neratinib, oral, was permitted by the U.S. Food and Drug Administration in July 2017 for the prolonged adjuvant therapy of grownup sufferers with early-stage HER2-overexpressed/amplified breast most cancers, following adjuvant trastuzumab-based remedy, and is marketed in the US as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was additionally permitted by the FDA together with capecitabine for the therapy of grownup sufferers with superior or metastatic HER2-constructive breast cancer who’ve acquired two or extra prior anti-HER2-based mostly regimens within the metastatic setting. NERLYNX was granted advertising authorization by the European Commission in August 2018 for the prolonged adjuvant therapy of grownup sufferers with early-stage hormone receptor-optimistic HER2-overexpressed/amplified breast cancer and who’s lower than 1 year from the conclusion of prior adjuvant trastuzumab-based remedy.